Cytolytic T-cell clones against an autologous human melanoma: specificity study and definition of three antigens by immunoselection - PubMed (original) (raw)
Case Reports
Cytolytic T-cell clones against an autologous human melanoma: specificity study and definition of three antigens by immunoselection
A Knuth et al. Proc Natl Acad Sci U S A. 1989 Apr.
Abstract
Cytolytic T-lymphocyte (CTL) clones against an autologous melanoma (SK-MEL-29) were generated by mixed lymphocyte tumor culture and subsequent cloning of responder lymphocytes at limiting dilutions. These CTL clones lysed autologous melanoma but not autologous Epstein-Barr virus-transformed B cells and none of the allogeneic tumor targets included in the specificity analysis. The lysis of autologous melanoma targets could be inhibited by monoclonal antibodies against monomorphic HLA class I determinants. For proliferation of CTLs, the stimulation with the relevant target antigen on autologous tumor cells was essential. Immunoselection experiments carried out with two CTL clones revealed the existence of melanoma subclones that were resistant to lysis by the CTL clones used for immunoselection but were still lysed by other autologous CTL clones. This analysis allowed us to identify three stable simultaneously expressed antigens on the melanoma cells defined by autologous CTLs.
Similar articles
- Lysis of human melanoma cells by autologous cytolytic T cell clones. Identification of human histocompatibility leukocyte antigen A2 as a restriction element for three different antigens.
Wölfel T, Klehmann E, Müller C, Schütt KH, Meyer zum Büschenfelde KH, Knuth A. Wölfel T, et al. J Exp Med. 1989 Sep 1;170(3):797-810. doi: 10.1084/jem.170.3.797. J Exp Med. 1989. PMID: 2788708 Free PMC article. - Antigenic heterogeneity of a human melanoma tumor detected by autologous CTL clones.
Degiovanni G, Lahaye T, Hérin M, Hainaut P, Boon T. Degiovanni G, et al. Eur J Immunol. 1988 May;18(5):671-6. doi: 10.1002/eji.1830180503. Eur J Immunol. 1988. PMID: 2967757 - Genes coding for tumor antigens recognized by human cytolytic T lymphocytes.
Coulie PG, Weynants P, Lehmann F, Herman J, Brichard V, Wölfel T, Van Pel A, De Plaen E, Brasseur F, Boon T. Coulie PG, et al. J Immunother Emphasis Tumor Immunol. 1993 Aug;14(2):104-9. doi: 10.1097/00002371-199308000-00004. J Immunother Emphasis Tumor Immunol. 1993. PMID: 8280701 Review. - Antitumor immunity at work in a melanoma patient.
Coulie PG, Ikeda H, Baurain JF, Chiari R. Coulie PG, et al. Adv Cancer Res. 1999;76:213-42. doi: 10.1016/s0065-230x(08)60778-2. Adv Cancer Res. 1999. PMID: 10218103 Review.
Cited by
- Potential Immunotherapy Targets for Liver-Directed Therapies, and the Current Scope of Immunotherapeutics for Liver-Related Malignancies.
Charles J, Vrionis A, Mansur A, Mathias T, Shaikh J, Ciner A, Jiang Y, Nezami N. Charles J, et al. Cancers (Basel). 2023 May 5;15(9):2624. doi: 10.3390/cancers15092624. Cancers (Basel). 2023. PMID: 37174089 Free PMC article. Review. - Can Immune Suppression and Epigenome Regulation in Placenta Offer Novel Insights into Cancer Immune Evasion and Immunotherapy Resistance?
Hossain SM, Lynch-Sutherland CF, Chatterjee A, Macaulay EC, Eccles MR. Hossain SM, et al. Epigenomes. 2021 Jul 25;5(3):16. doi: 10.3390/epigenomes5030016. Epigenomes. 2021. PMID: 34968365 Free PMC article. Review. - PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8+ T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients.
Naing A, Infante JR, Papadopoulos KP, Chan IH, Shen C, Ratti NP, Rojo B, Autio KA, Wong DJ, Patel MR, Ott PA, Falchook GS, Pant S, Hung A, Pekarek KL, Wu V, Adamow M, McCauley S, Mumm JB, Wong P, Van Vlasselaer P, Leveque J, Tannir NM, Oft M. Naing A, et al. Cancer Cell. 2018 Nov 12;34(5):775-791.e3. doi: 10.1016/j.ccell.2018.10.007. Cancer Cell. 2018. PMID: 30423297 Free PMC article. - Tumor-Derived Apoptotic Vesicles: With Death They Do Part.
Muhsin-Sharafaldine MR, McLellan AD. Muhsin-Sharafaldine MR, et al. Front Immunol. 2018 May 7;9:957. doi: 10.3389/fimmu.2018.00957. eCollection 2018. Front Immunol. 2018. PMID: 29780392 Free PMC article. Review. - Consequences of point mutations in melanoma-associated antigen 4 (MAGE-A4) protein: Insights from structural and biophysical studies.
Hagiwara Y, Sieverling L, Hanif F, Anton J, Dickinson ER, Bui TT, Andreeva A, Barran PE, Cota E, Nikolova PV. Hagiwara Y, et al. Sci Rep. 2016 Apr 28;6:25182. doi: 10.1038/srep25182. Sci Rep. 2016. PMID: 27121989 Free PMC article.
References
- Proc Natl Acad Sci U S A. 1976 Sep;73(9):3278-82 - PubMed
- Eur J Cancer Clin Oncol. 1987 Jun;23(6):697-706 - PubMed
- Cell. 1978 May;14(1):9-20 - PubMed
- Proc Natl Acad Sci U S A. 1978 Oct;75(10):5122-6 - PubMed
- Int J Cancer. 1979 Jul 15;24(1):34-44 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials